Skip to content

Pharmacokinetic Study of Terpinolene in Healthy Subjects (PKT Study)

Pharmacokinetic Study of Terpinolene in Healthy Subjects (PKT Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06691126
Enrollment
11
Registered
2024-11-15
Start date
2024-11-04
Completion date
2024-12-03
Last updated
2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacokinetics of Terpinolene

Brief summary

The study aims to check if our prediction about the uptake, distribution, and elimination of terpinolene (a food additive commonly found in e.g. fruits and herbs) from the human body is accurate.

Detailed description

Traditionally, the toxicological hazards of chemical substances have been identified and evaluated using animal studies. With the global shift towards limiting the use of animals in human safety assessment, Next Generation Risk Assessment (NGRA) has been conceptualized as a human-relevant, exposure-led approach integrating in silico, in chemico and in vitro methodologies. Consequently, in silico physiologically based pharmacokinetic (PBPK) modelling strategies have emerged as a central component of the NGRA paradigm. By mapping compound behaviour (i.e. absorption, distribution, metabolism and excretion) in the body to a physiologically realistic compartmental structure comprising various organs connected by the circulating blood system, PBPK models (i) provide the link between in vitro hazard data and human-relevant exposures and (ii) enable conversion of external doses to internal exposures which can then be compared to internal thresholds of toxicological concern (iTTC). Established methods exist to develop a PBPK model for any chemical based solely on in vitro and in silico parameters. However, assessment of the predictive accuracies of any PBPK model-derived simulations is highly reliant on the availability of in vivo pharmacokinetic (PK) datasets. This inherently limits the widespread applicability of PBPK modelling to the vast chemical space of non-pharmacological entities whereby there is a paucity of in vivo data. To circumvent this limitation, Ellison et al. introduced a read across framework for evaluating the PBPK model of a target chemical (chemical with no PK data) using PK data from an analogous source chemical (chemical with existing PK data). In this study, the investigator aims to further evaluate and develop this PK read-across approach to consider non-pharmaceutical compounds. A target compound with no human PK data available was identified, which is a food flavouring agent, terpinolene and its source compound, limonene. A PBPK model for terpinolene will be built and used to compare the in vitro absorption, distribution, metabolism and elimination (ADME) parameters between terpinolene and limonene. To further validate this read-across approach, a prospective clinical study to obtain the missing in vivo PK of terpinolene is proposed.

Interventions

OTHERTerpinolene in olive oil

Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil

Sponsors

Institute for Human Development and Potential (IHDP), Singapore
CollaboratorOTHER
Singapore Institute of Food and Biotechnology Innovation
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

The study will be carried out as a single arm, unblinded, PK study. The total duration of the study is about 24 hours, excluding screening and enrolment time (up to 1 hour).

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 21-50 * Chinese, Malay and Indian ethnicities * Male or female * Adequate fluency in the English language to understand the informed consent process, study instructions and study assessments * Sufficient vision and hearing to complete the study procedures * Willing and able to participate and to give written informed consent

Exclusion criteria

* Past (\<3 months prior to the study) or current major metabolic, endocrine, gastrointestinal or cardiovascular disease * Individuals diagnosed with non-alcoholic fatty liver disease * Major surgery in the past 2 months * On chronic medication * Allergy to olive oil * Vegetarian/vegan * Smoking * Pregnant or lactating * Alcohol intake \>1 units per day * Body Mass Index \<18.5 kg/m2 or ≥27 kg/m2 * Body weight \<54 kg * Member of the study team or their immediate family members

Design outcomes

Primary

MeasureTime frameDescription
Plasma terpinolene concentration24 hoursBlood samples will be collected at 9 timepoints

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026